Neil Gregory Almstead

Companies

• PTC TherapeuticsSenior VP, Research and CMC Jun 19, 2013 to now¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• PTC Therapeutics PTCT63,198 shares²$3.9M at $60.99Jul 13, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Jul 9, 2026Sold 2,464 shares at $90.25 of PTC Therapeutics²
• Jul 9, 2026Exercised options 2,464 shares at $46.54 of PTC Therapeutics²
• Jul 7, 2026Sold 9,288 shares at $89.44 of PTC Therapeutics³
• Jul 7, 2026Sold 11,369 shares at $89.03 of PTC Therapeutics³
• Jul 7, 2026Sold 3,956 shares at $87.17 of PTC Therapeutics³
• Jul 7, 2026Exercised options 24,613 shares at $39.42 of PTC Therapeutics³
• Jul 6, 2026Sold 2,474 shares at $87.03 of PTC Therapeutics³
• Jul 6, 2026Exercised options 2,474 shares at $39.42 of PTC Therapeutics³
• Jul 6, 2026Sold 10,090 shares at $86.32 of PTC Therapeutics³
• Jul 6, 2026Sold 8,786 shares at $85.35 of PTC Therapeutics³
• Jul 6, 2026Exercised options 18,876 shares at $38.10 of PTC Therapeutics³
• Jul 6, 2026Sold 385 shares at $86.34 of PTC Therapeutics³
• Jul 6, 2026Sold 426 shares at $85.28 of PTC Therapeutics³
• Jul 6, 2026Exercised options 811 shares at $38.10 of PTC Therapeutics³
• Jun 26, 2026Sold 7,718 shares at $85.26 of PTC Therapeutics⁴
• Jun 26, 2026Exercised options 7,718 shares at $38.10 of PTC Therapeutics⁴
• Jun 26, 2026Sold 412 shares at $85.23 of PTC Therapeutics⁴
• Jun 26, 2026Exercised options 412 shares at $38.10 of PTC Therapeutics⁴
• Jun 25, 2026Sold 100 shares at $87.00 of PTC Therapeutics⁵
• Jun 25, 2026Exercised options 100 shares at $39.42 of PTC Therapeutics⁵
• Jun 25, 2026Sold 11,337 shares at $86.51 of PTC Therapeutics⁵
• Jun 25, 2026Sold 8,522 shares at $85.26 of PTC Therapeutics⁵
• Jun 25, 2026Exercised options 19,859 shares at $38.10 of PTC Therapeutics⁵
• Jun 25, 2026Sold 419 shares at $86.39 of PTC Therapeutics⁵
• Jun 25, 2026Sold 582 shares at $85.24 of PTC Therapeutics⁵